Side Effects of doxercalciferol injection: A Synthesis of Findings from 1 Studies

  1. Home
  2. Side Effects of doxercalciferol injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of doxercalciferol injection: A Synthesis of Findings from 1 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of doxercalciferol injection: A Synthesis of Findings from 1 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Findings

This study compared the effectiveness and safety of oral versus intravenous doxercalciferol in hemodialysis patients with secondary hyperparathyroidism. The study enrolled 70 patients who received both oral and intravenous doxercalciferol treatment for 12 weeks after an 8-week washout period. Both treatments led to a significant reduction in iPTH levels, indicating therapeutic effectiveness. 1

Reasons for Side Effects

Doxercalciferol is an active form of vitamin D that promotes calcium absorption from the gut, increases calcium deposition in bones, and suppresses parathyroid hormone secretion. Excessive administration or patients with calcium metabolic disorders may experience side effects such as hypercalcemia and hyperphosphatemia. 1

Common Side Effects

Hypercalcemia

During oral doxercalciferol treatment, 3.62% of calcium measurements showed serum calcium levels exceeding 11.2 mg/dL, compared to 0.86% during intravenous doxercalciferol treatment. 1

Hyperphosphatemia

Serum phosphorus levels tended to be higher during oral doxercalciferol treatment compared to intravenous doxercalciferol treatment. 1

Side Effects Management

Hypercalcemia

Hypercalcemia can be improved by reducing the dosage of doxercalciferol. In severe cases, administering calcium chelating agents may be necessary. 1

Hyperphosphatemia

Hyperphosphatemia can be improved through administration of phosphate binders and dietary modifications. 1

Comparison Across Studies

Commonalities

This study, along with others, has explored the effectiveness and safety of oral and parenteral vitamin D analogs in hemodialysis patients with secondary hyperparathyroidism. Both methods have demonstrated efficacy in reducing iPTH levels. 1

Differences

Compared to oral doxercalciferol, intravenous doxercalciferol exhibited lower incidences of hypercalcemia and smaller increases in serum phosphorus levels. 1

Real-World Application Precautions

Doxercalciferol can be an effective treatment for hemodialysis patients with secondary hyperparathyroidism. However, potential side effects such as hypercalcemia and hyperphosphatemia should be taken into account. 1

Limitations of Current Research

This study was relatively small, and long-term safety and effectiveness remain unknown. 1

Future Research Directions

Large-scale studies are needed to evaluate the long-term safety and effectiveness of doxercalciferol. Optimization research regarding the dosage and administration methods of doxercalciferol is also required. 1

Conclusion

Intravenous doxercalciferol may be a safer treatment option for hemodialysis patients with secondary hyperparathyroidism compared to oral doxercalciferol, demonstrating lower incidences of side effects such as hypercalcemia and hyperphosphatemia. 1

Literature analysis of 1 papers
Positive Content
1
Neutral Content
0
Negative Content
0
Article Type
0
0
0
0
1
1.

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Author: MaungH M, ElangovanL, FrazãoJ M, BowerJ D, KelleyB J, AcchiardoS R, RodriguezH J, NorrisK C, SigalaJ F, RutkowskiM, RobertsonJ A, GoodmanW G, LevineB S, ChesneyR W, MazessR B, KylloD M, DouglassL L, BishopC W, CoburnJ W

Reduced hypercalcemia
iPTH suppression
Hyperphosphatemia

Intravenous doxercalciferol (1alphaD(2)) effectively reduced parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Compared to oral doxercalciferol, intravenous administration resulted in less frequent hypercalcemia and less increase in serum phosphorus levels.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.